SCHEMBL20511717

SCHEMBL20511717

CNS(=O)(=O)N[C@H]1CCc2c(C(=O)Nc3ccc(F)c(Cl)c3)ccc(F)c21

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.47
▸ MAPT P10636 8/20 0.46
▸ TP53 P04637 4/20 0.46
▸ LMNA P02545 4/20 0.46
▸ FADS1 O60427 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NR1I2 O75469 1/20 0.40
▸ AHR P35869 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29656495 1.00 KMT2A (0.47) KMT2AMAPTTP53LMNAFADS1
SCHEMBL29351726 0.90 KMT2A (0.47) KMT2AMAPTTP53LMNAFADS1
SCHEMBL26597378 0.90 KMT2A (0.47) KMT2AMAPTTP53LMNAFADS1
SCHEMBL29656407 0.90 KMT2A (0.47) KMT2AMAPTTP53LMNAFADS1
SCHEMBL29353436 0.90 KMT2A (0.51) KMT2AMAPTTP53LMNAFADS1
SCHEMBL20510100 0.90 KMT2A (0.51) KMT2AMAPTTP53LMNAFADS1
SCHEMBL29655943 0.90 KMT2A (0.51) KMT2AMAPTTP53LMNAFADS1
SCHEMBL21465702 0.90 KMT2A (0.45) KMT2AMAPTTP53LMNAFADS1
SCHEMBL29655938 0.90 KMT2A (0.45) KMT2AMAPTTP53LMNAFADS1
SCHEMBL29353443 0.90 KMT2A (0.45) KMT2AMAPTTP53LMNAFADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601216-B1 SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION ARBUTUS BIOPHARMA CORP (CA) 2023-10-25 — — EP claimed
EP-3601216-B1 SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION ARBUTUS BIOPHARMA CORP (CA) 2023-10-25 — — EP disclosed
EP-3601216-B1 SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION ARBUTUS BIOPHARMA CORP (CA) 2023-10-25 — — EP disclosed
CN-116472063-A Targeted conjugates comprising modified siRNAs 阿布特斯生物制药公司 2023-07-21 — — CN disclosed
CN-113874373-A Therapeutic methods for the treatment of hepatitis B 阿布特斯生物制药公司 2021-12-31 — — CN disclosed
EP-3601216-A1 SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2020-02-05 — — EP disclosed
WO-2018172852-A1 SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2018-09-27 — — WO disclosed
Send feedback